Advertisement
ORGO vs PRGO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORGO is a StrongBuy and PRGO is a Hold.
ORGO in +15.75% Uptrend, growing for three consecutive days on November 11, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ORGO advanced for three days, in 189 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORGO's RSI Oscillator exited the oversold zone, 22 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on ORGO as a result. In 58 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ORGO just turned positive on November 04, 2026. Looking at past instances where ORGO's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ORGO broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ORGO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.706) is normal, around the industry mean (6.379). P/E Ratio (-1.043) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.404) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. ORGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
PRGO's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for PRGO moved out of overbought territory on November 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 26 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
PRGO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on PRGO as a result. In 58 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for PRGO just turned positive on November 10, 2026. Looking at past instances where PRGO's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
Following a +7.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRGO advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 120 of 204 cases where PRGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.874) is normal, around the industry mean (6.379). P/E Ratio (-1.266) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.142) is also within normal values, averaging (2.202). Dividend Yield (0.073) settles around the average of (0.062) among similar stocks. P/S Ratio (0.454) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PRGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ORGO | PRGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 90 | 36 | |
P/E GROWTH RATING 1..100 | 98 | 90 | |
SEASONALITY SCORE 1..100 | 50 | 20 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRGO's Valuation (9) in the Pharmaceuticals Other industry is in the same range as ORGO (36) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
PRGO's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ORGO (100) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
PRGO's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ORGO (98) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
PRGO's Price Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (90) in the Financial Conglomerates industry. This means that PRGO’s stock grew somewhat faster than ORGO’s over the last 12 months.
PRGO's P/E Growth Rating (90) in the Pharmaceuticals Other industry is in the same range as ORGO (98) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
| ORGO | PRGO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 63% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 63% |
| Advances ODDS (%) | 2 days ago 75% | 4 days ago 64% |
| Declines ODDS (%) | 7 days ago 88% | 2 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORGO’s FA Score shows that 0 FA rating(s) are green while PRGO’s FA Score has 1 green FA rating(s).
- ORGO’s FA Score: 0 green, 5 red.
- PRGO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORGO’s TA Score shows that 4 TA indicator(s) are bullish while PRGO’s TA Score has 4 bullish TA indicator(s).
- ORGO’s TA Score: 4 bullish, 4 bearish.
- PRGO’s TA Score: 4 bullish, 4 bearish.
Price Growth
ORGO (@Pharmaceuticals: Generic) experienced а +20.69% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was +4.55% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.
Reported Earning Dates
ORGO is expected to report earnings on Mar 04, 2027.
PRGO is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.13% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ORGO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIK could also see price increases.
| Ticker / NAME | Correlation To ORGO | 1D Price Change % | ||
|---|---|---|---|---|
| ORGO | 100% | +12.28% | ||
| ANIK - ORGO | 36% Loosely correlated | +3.56% | ||
| PRGO - ORGO | 31% Poorly correlated | -1.66% | ||
| ACET - ORGO | 29% Poorly correlated | -0.33% | ||
| ANIP - ORGO | 24% Poorly correlated | -0.22% | ||
| IRWD - ORGO | 23% Poorly correlated | +1.25% | ||
More | ||||
PRGO and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with SUPN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then SUPN could also see price increases.
| Ticker / NAME | Correlation To PRGO | 1D Price Change % | ||
|---|---|---|---|---|
| PRGO | 100% | -1.66% | ||
| SUPN - PRGO | 49% Loosely correlated | +2.43% | ||
| ELAN - PRGO | 37% Loosely correlated | -1.05% | ||
| EVO - PRGO | 35% Loosely correlated | N/A | ||
| ALVO - PRGO | 34% Loosely correlated | +0.82% | ||
| TAK - PRGO | 31% Poorly correlated | -0.43% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MRAL | 14.54 | 1.13 | +8.43% |
| GraniteShares 2x Long MARA Daily ETF (MRAL) | |||
| IGPT | 82.06 | 3.96 | +5.07% |
| Invesco AI and Next Gen Software ETF (IGPT) | |||
| OALC | 40.66 | 0.58 | +1.45% |
| OneAscent Large Cap Core ETF (OALC) | |||
| XBJL | 41.13 | 0.33 | +0.82% |
| Innovator U.S. Equity Accelerated 9 Buffer ETF - July (XBJL) | |||
| XLKX | 16.64 | N/A | N/A |
| Corgi U.S. Technology 2x Daily ETF (XLKX) | |||